(Bloomberg) -- Pfizer, maker of a top-selling COVID vaccine, will buy all the shares of Trillium Therapeutics it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.
Pfizer will pay $18.50 a share for Cambridge-based Trillium, the companies said Monday in a statement. The price represents a 118 percent premium to the stock’s 60-day weighted average price. Shares of Trillium nearly tripled in trading before US markets opened, while Pfizer rose 3.7 percent.
Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.
Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease. They target CD47, a protein found on some cancer cells that cloaks them from the normal immune response, and send a signal activating the response.
Early clinical data for both molecules is encouraging and they’re expected to become another important backbone immunotherapy for multiple types of cancer, especially those of the blood, Chris Boshoff, Pfizer’s chief development officer for oncology, said in the statement.
Blood cancers represent 6 percent of all tumor diagnoses across the world, according to the statement. Last year, more than 1 million people worldwide were diagnosed with a form of blood cancer and more than 700,000 people died from the disease.
©2021 Bloomberg L.P.